Shares of Iambic Therapeutics fell after the company reported a wider loss in the recent quarter.
The stock declined 11%, to $11.60, on Monday. The company had its public debut last month, selling nearly 9.38 million shares of its common stock for $16 apiece.
The life-sciences and technology company before the bell widened its third-quarter loss to $38.5 million, or $8.52 a share, compared with a loss of $21.5 million, or $5.24 a share, a year earlier.
The wider loss came as total operating expenses jumped 52% to $41.5 million, driven by increased research and development costs as well as higher general and administrative expenses.
Iambic noted the recent quarter also included a $10.4 million non-cash charge tied to the change in fair value of convertible notes, which converted into shares of common stock immediately prior to the closing of its IPO.
Collaboration revenue more than doubled, coming in at $11.4 million. However, that is below the $21 million that analysts polled by FactSet expected.
Comments